(CRIS) Curis, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CRIS) Curis, Inc. Complete Analysis Pack
Go Beyond the Preview—Access the Full Reference Sources
This Curis, Inc. SWOT Analysis gives a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, investing, or presentations; the page already displays a real preview of the analysis so you can judge style and substance. Purchase the full version to download the complete ready-to-use report and save time on your decision-making.
Strengths
5 oncology programs
Curis has five named oncology programs: Emavusertib, CI-8993, Fimepinostat, CA-170, and CA-327. That gives the Company five shots on goal across cancer, which helps spread risk if one program stalls. A portfolio this broad can create more data readouts and partnering options than a single-asset story.
Emavusertib Phase 1/2
Emavusertib is an oral small molecule in Phase 1/2, with a broad hematology scope across non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. That gives Curis, Inc. three disease areas for clinical readouts, which can create multiple catalysts from one asset and widen its partnering appeal.
Erivedge partnered asset
Curis co-develops and markets Erivedge with Roche and Genentech, so it gets a branded cancer asset without carrying the full commercial burden. Erivedge is an oral small molecule that blocks the hedgehog signaling pathway and is approved for advanced basal cell carcinoma, giving Curis a real oncology revenue link. As of fiscal 2025, this partnered product still anchors Curis' commercial story and de-risks the platform versus a single preclinical asset.
Aurigene collaboration
Curis, Inc.'s Aurigene Discovery Technologies Limited deal broadens its reach beyond the internal pipeline by adding small-molecule programs in immuno-oncology and precision oncology. That matters because Curis, Inc. can tap Aurigene's discovery engine and spread R&D risk across more shots on goal. The partnership is a real strength when capital is tight and pipeline depth drives value.
- Expands Curis, Inc. beyond internal assets
- Covers immuno-oncology and precision oncology
- Improves pipeline breadth and risk sharing
Founded 2000
Curis, Inc., founded in 2000 and based in Lexington, Massachusetts, has a 26-year operating history in 2026. That long run supports scientific continuity, trial know-how, and partner trust. For a biotech company, that kind of staying power can help when programs take years to move from research to clinic.
- Founded in 2000
- Headquartered in Lexington, Massachusetts
- 26 years of operating history in 2026
- Supports scientific and partnership credibility
Curis’ Diversified Pipeline and Erivedge Anchor Long-Term Growth
Curis, Inc.'s strength is a diversified oncology pipeline with five named programs and one commercial asset, Erivedge, which helps balance early-stage risk with recurring product revenue. The Aurigene partnership adds external discovery depth in immuno-oncology and precision oncology, while a 26-year operating history supports trial execution and partner credibility.
| Strength | Data |
|---|---|
| Pipeline | 5 programs |
| Commercial asset | Erivedge |
| History | Founded 2000 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Curis, Inc.’s business strategy
Editable Excel File
Provides a quick Curis, Inc. SWOT snapshot to simplify strategic decision-making.
Reference Sources
Provides a concise, traceable bibliography of primary industry reports, regulatory filings, and datasets to speed due diligence and verify Curis, Inc. assumptions.
Weaknesses
Clinical-stage portfolio
Curis, Inc. still has 0 marketed products, and most of its pipeline remains in clinical or pre-IND stages in 2025. That leaves the company highly exposed to trial success, regulatory risk, and funding needs. With no broad internal commercial franchise, revenue diversification is still missing, so setbacks in one program can hit valuation fast.
Emavusertib still early
Emavusertib is still in Phase 1/2, so Curis, Inc. has not yet de-risked it with late-stage Phase 3 or registration data. That keeps clinical readout risk high, since early trials can show activity that does not hold up in larger studies. Until pivotal data arrives, the program remains a pipeline asset, not a proven value driver.
CA-327 pre-IND
CA-327 remains in the pre-IND stage, so Curis, Inc. still has 0 human efficacy or safety data to support the program. That makes it a high-uncertainty asset, because the FDA must clear an IND before any first-in-human trial can start. In practical terms, that can mean many months or longer before clinical readouts begin.
Oncology-only focus
Curis, Inc. is still a pure oncology story, with its pipeline tied to hematologic malignancies and solid tumors and no programs outside cancer. That means 100% of its R&D and clinical risk sits in one therapeutic market, so any setback in oncology data, pricing, or trial timing can hit the whole company at once. One market, one exposure.
- 100% focused on cancer therapeutics
- No non-oncology diversification
- Pipeline limited to 2 cancer buckets
- Higher risk if oncology trials miss
Partner reliance
Curis, Inc.’s weakness is partner reliance: Erivedge is co-developed and co-marketed with Roche and Genentech, so Curis does not fully control launch timing, pricing, or execution on its only marketed asset. That leaves Curis exposed to decisions made by 2 larger partners instead of 1 company.
- Erivedge depends on Roche and Genentech.
- Aurigene also supports external innovation.
- Partner moves can shift timing and economics.
If a partner slows spend or changes priorities, Curis can lose speed, cash flow, and leverage fast. This makes its business model less flexible and more exposed than a fully owned portfolio.
Curis: No Products, Big Risk, All on One Pipeline
Curis, Inc. still has 0 marketed products, so 2025 value depends on a very small pipeline and no diversified revenue base. Emavusertib is still only in Phase 1/2, while CA-327 remains pre-IND, leaving the company exposed to trial failure, FDA delays, and funding pressure. One market, one risk.
| Weakness | 2025 data |
|---|---|
| Marketed products | 0 |
| Clinical assets | 2 |
| Oncology focus | 100% |
| Lead program | Phase 1/2 |
What You See Is What You Get
Curis, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version with in-depth insights on Curis, Inc.
Opportunities
Hematology expansion
Emavusertib is in development across 3 blood cancer settings: non-Hodgkin lymphomas, AML, and MDS. That gives Curis, Inc. a wider path to value, since positive data in one program can support expansion into the others. In hematologic oncology, even a single clear signal can broaden the drug’s case fast.
MYC-altered DLBCL
Fimepinostat’s focus on MYC-altered diffuse large B-cell lymphoma targets a biomarker-defined slice of a disease that makes up about 30% of non-Hodgkin lymphoma cases, or roughly 25,000 new U.S. cases a year. That narrow positioning can support stronger differentiation if Curis shows clear activity in this high-risk subgroup. For a small-cap biotech with limited cash, a defined niche can also improve partnering odds if the data are convincing.
Solid tumor coverage
CA-170 is being studied in advanced solid tumors and lymphomas, so Curis, Inc. is not tied to one cancer type. That wider label can open more study cohorts and speed patient finding, since solid tumors make up about 90% of adult cancers. For Curis, Inc., broader coverage can support more trial shots without relying on a single subgroup.
New IND pathway
CA-327 is still pre-IND, but moving it into clinical testing would add 1 new asset to Curis, Inc.'s pipeline and widen its shot on goal. That matters because the IND step is the gate to human trials, so this move could lift long-term pipeline depth and reduce reliance on a small number of programs.
- 1 new clinical asset if CA-327 advances
- Pre-IND today, so upside is still early
- IND filing would expand pipeline depth
Hedgehog franchise
Curis, Inc.'s Hedgehog franchise still has room to create value because Erivedge already has an approved advanced basal cell carcinoma use, and a partner can keep driving sales without heavy Curis spend. Roche has reported Erivedge sales in recent years at roughly the low- to mid-hundreds of millions of dollars, which shows the asset remains commercially relevant. The franchise also backs Curis, Inc.'s cancer-focused story and gives the pipeline more credibility.
- Approved advanced basal cell carcinoma use
- Partner-led sales lower Curis, Inc. cost
- Roche sales show real market demand
- Supports Curis, Inc.'s oncology focus
Curis Pipeline Offers Multiple Shots at Hematology Upside
Curis, Inc. still has upside from a broader hematology pipeline: emavusertib spans 3 blood cancer settings, while fimepinostat targets MYC-altered DLBCL, about 30% of NHL. CA-170 adds solid-tumor reach, and CA-327 could add 1 more clinical asset if it reaches IND.
| Asset | Opportunity |
|---|---|
| Emavusertib | 3 settings |
| Fimepinostat | 30% of NHL |
| CA-327 | 1 more asset |
Threats
Clinical failure risk
Curis, Inc. faces high clinical failure risk because all five key programs—emavusertib, CI-8993, fimepinostat, CA-170, and CA-327—are still in development. Any safety signal or weak efficacy readout could stop trials, cut partnering odds, and erase value fast. For a clinical-stage biotech with no marketed product, one failed study can change the whole pipeline.
Crowded oncology market
Curis, Inc. faces a crowded oncology field: NHL, AML, MDS, DLBCL, and solid tumors already draw heavy biotech and pharma spending. The global oncology drug market was about $250 billion in 2025, and competition is still rising, so even strong data can face pricing pressure and faster substitution. That can cap Curis, Inc.’s peak sales and reduce partner interest.
Regulatory hurdles
Oncology is one of the toughest FDA paths: cancer drugs often take 8-12 years to reach approval, so Curis, Inc.'s Phase 1/2 and pre-IND assets can stall for years. Roughly 90% of oncology candidates fail before approval, which makes regulatory risk a real threat to value creation. Any delay in IND work or patient enrollment can push out milestones and raise funding pressure.
Partner execution risk
Curis depends on Roche and Genentech for Erivedge co-development and marketing, so any shift in their priorities could slow sales and weaken the program. In Curis’ 2024 Form 10-K, revenue was $5.5 million, showing how exposed the Company is to partner execution. Aurigene is also key to pipeline innovation, so delays or funding changes there can hit momentum fast.
Partner priority shifts can slow Erivedge growth.
Aurigene risk can weaken pipeline output.
Low revenue magnifies execution risk.
Pipeline concentration risk
Curis’s oncology story is concentrated in one lead clinical asset and a very small pipeline, so a miss in emavusertib or any other key program could hit valuation hard. With only a few shots on goal, there is less room for a trial failure, slower enrollment, or a safety issue to be offset by another asset.
- One lead asset drives most value
- Few backup programs raise risk
- Any setback can move the stock sharply
Curis Faces High Pipeline and Funding Risk
Curis, Inc. remains exposed to clinical and funding risk because its value still hinges on a small, mostly early-stage pipeline, led by emavusertib. A single weak efficacy readout or safety issue could hit valuation fast. Partner dependence also adds risk if Roche, Genentech, or Aurigene shift priorities.
| Threat | Data point |
|---|---|
| Revenue base | 2024 revenue: $5.5 million |
| Market pressure | Oncology market: about $250 billion in 2025 |
| Pipeline risk | Most assets still in Phase 1/2 or pre-IND |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.